180 related articles for article (PubMed ID: 1868438)
1. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.
Maki PA; Sladek NE
Biochem Pharmacol; 1993 Jan; 45(1):231-9. PubMed ID: 8424816
[TBL] [Abstract][Full Text] [Related]
3. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.
Kohn FR; Landkamer GJ; Manthey CL; Ramsay NK; Sladek NE
Cancer Res; 1987 Jun; 47(12):3180-5. PubMed ID: 3034402
[TBL] [Abstract][Full Text] [Related]
4. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
5. Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification.
Manthey CL; Landkamer GJ; Sladek NE
Cancer Res; 1990 Aug; 50(16):4991-5002. PubMed ID: 2379164
[TBL] [Abstract][Full Text] [Related]
6. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
7. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
8. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
9. Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide.
Sreerama L; Sladek NE
Drug Metab Dispos; 1995 Oct; 23(10):1080-4. PubMed ID: 8654195
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3.
Giorgianni F; Bridson PK; Sorrentino BP; Pohl J; Blakley RL
Biochem Pharmacol; 2000 Aug; 60(3):325-38. PubMed ID: 10856427
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
Phelan ET; Vietti TJ; Valeriote FA; Coulter D
Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853
[TBL] [Abstract][Full Text] [Related]
13. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.
Hilton J
Cancer Res; 1984 Nov; 44(11):5156-60. PubMed ID: 6488175
[TBL] [Abstract][Full Text] [Related]
14. Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia.
Swaffar DS; Horstman MG; Jaw JY; Thrall BD; Meadows GG; Harker WG; Yost GS
Cancer Res; 1989 May; 49(9):2442-7. PubMed ID: 2706632
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.
Rekha GK; Sreerama L; Sladek NE
Biochem Pharmacol; 1994 Nov; 48(10):1943-52. PubMed ID: 7986206
[TBL] [Abstract][Full Text] [Related]
16. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines.
Dockham PA; Sreerama L; Sladek NE
Drug Metab Dispos; 1997 Dec; 25(12):1436-41. PubMed ID: 9394035
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells.
Tsukamoto N; Chen J; Yoshida A
Blood Cells Mol Dis; 1998 Jun; 24(2):231-8. PubMed ID: 9714700
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells.
Russo JE; Hilton J
Cancer Res; 1988 Jun; 48(11):2963-8. PubMed ID: 3365687
[TBL] [Abstract][Full Text] [Related]
19. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde.
Dockham PA; Lee MO; Sladek NE
Biochem Pharmacol; 1992 Jun; 43(11):2453-69. PubMed ID: 1610409
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells.
Erikson JM; Tweedie DJ; Ducore JM; Prough RA
Cancer Res; 1989 Jan; 49(1):127-33. PubMed ID: 2908840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
